Table 3.
Characteristics of 10 palivizumab (PZ) recipiants with recorded dosing schedules.
| RSV subgroup | CDC RSV rRT-PCR Ct valuea | Nt substitution | Predicted AA substitution | Age (months) | Days ill before enrollment | PZ dates | # PZ doses | Date of hospitalization or outpatient visit | Breakthrough (Y/N)c |
|---|---|---|---|---|---|---|---|---|---|
| A | 22.2 | 6 | 8 | last on 12/13/05 | 2 | 2/7/06 | N | ||
| B | 27.2 | 19 | 7 | 11/?/07 | 1 | 1/17/08b | N | ||
| B | 17.3 | 2 | 10 | 2/?/08 | 1 | 2/21/08 | ?d | ||
| B | 19.3 | 4 | 4 | 3/4/05 | 1 | 3/27/05 | Y | ||
| B | 26.0 | 12 | 3 | 12/2/05 | 1 | 12/15/05 | Y | ||
| A | 23.1 | 14 | 5 | 11/?/05, 12/?/05, 1/?/06 | 2 or 3 | 1/15/06 | Y | ||
| A | 23.9 | A814G | K272E | 9 | 4 | 11/?/05, 12/?/05, 1/?/06, 2/?/06 | 3 or 4 | 2/6/06 | Y |
| B | 18.5 | 6 | 2 | 11/?/07, 12/?/07, 1/?/08 | 2 or 3 | 1/7/08 | Y | ||
| B | 18.0 | 9 | 3 | 11/20/07, 12/18/07, 1/16/08 | 3 | 2/6/08b | Y | ||
| B | 22.7 | 18 | 7 | 12/3/07, 12/31/07, 1/8/08, 2/29/08 | 4 | 3/11/08 | Y |
a
Real-time RT-PCR Ct, cycle threshold value; positive test result, Ct < 40.
b
Outpatient visit.
c
Breakthrough, RSV hospitalization occurring <1 month after most recent PZ dose.
d
Breakthrough status could not be determined.